BioCentury | Feb 16, 2021
Deals

Feb. 16 Quick Takes: Cytovia, Cellectis partner on TALEN-edited NK cells; plus Cend-Qilu, Iterion and Woodford

Cytovia Therapeutics Inc. and Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) began a strategic R&D collaboration to develop induced pluripotent stem cell-derived NK and CAR-NK cell therapies using TALEN gene editing. Cellectis will receive $15 million in Cytovia equity...
BioCentury | Nov 6, 2020
Targets & Mechanisms

Data Byte: newly identified host factors that regulate ACE2 expression

Several recent publications highlighting host factors that modulate ACE2 expression point to possible new targets for COVID-19 therapies.  ACE2 and TMPRSS2 are the most common host targets of...
BioCentury | Apr 22, 2020
Product Development

FDA clears LabCorp’s COVID-19 home collection kits as Congress looks to bolster testing with $25B

...10 U.S. sites in its randomized, double-blind, placebo-controlled Phase II trial of ATYR1923. ATYR1923 modulates NRP2...
...Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Targets NRP2 - Neuropilin 2 Elizabeth...
BioCentury | Jul 18, 2019
Distillery Therapeutics

Small molecule NPR1 inhibitors for itch

DISEASE CATEGORY: Dermatology INDICATION: Itch NIH researchers identified 15 small molecule human NPR1 inhibitors through cell-based screening that could treat itch. The compounds inhibited NRP1, a receptor for a neuropeptide that promotes itch, with IC...
BioCentury | Dec 21, 2018
Company News

Astellas exercises option to acquire Potenza

Astellas Pharma Inc. (Tokyo:4503) exercised an exclusive option under an April 2015 deal and acquired Potenza Therapeutics Inc. (Cambridge, Mass.) (see "Potenza Therapeutics, Astellas Deal" ). Potenza received $164.6 million up front and is eligible...
BioCentury | Nov 26, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Peptides; polymers An amphiphilic dendrimer-peptide construct could be used for tumor-targeted delivery of siRNA therapies. The construct has four components: an amphiphilic dendrimer complex for loading with siRNA cargo; a peptide composed of repeating...
BioCentury | Aug 9, 2018
Preclinical News

New biological insight could lead to obesity treatment

By identifying a mechanism in dietary fat uptake, researchers from Yale University School of Medicine suggest a compound marketed for glaucoma could have therapeutic applications in obesity. The study was published Thursday in Science. Dietary...
BioCentury | Dec 5, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest inhibiting NRP1 in microglia and peripheral macrophages could help treat glioma. In a bone marrow-ablated mouse model of glioma, bone marrow transplants engineered to produce NRP1-knockout macrophages decreased tumor...
BioCentury | Jan 12, 2017
Emerging Company Profile

Looking beyond VEGF

SemaThera Inc. launched this week to develop a recombinant SEMA3A trap to treat vascular pathologies in the large fraction of diabetic macular edema (DME) patients who don’t respond to marketed anti- VEGF therapies. Semaphorins are...
BioCentury | Jan 3, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus In silico , in vitro and mouse studies suggest a peptide inhibitor of Staphylococcus aureus Sav1754 could help treat methicillin-resistant S. aureus (MRSA) infection. Bioinformatics analyses of human pathogenic and commensal bacterial genomes for...
Items per page:
1 - 10 of 143